- Home
- HOG vs HCM Comparison
HOG vs HCM Comparison
Compare HOG & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOG
- HCM
- Stock Information
- Founded
- HOG 1903
- HCM 2000
- Country
- HOG United States
- HCM Hong Kong
- Employees
- HOG N/A
- HCM N/A
- Industry
- HOG Motor Vehicles
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- HOG Consumer Discretionary
- HCM Health Care
- Exchange
- HOG Nasdaq
- HCM Nasdaq
- Market Cap
- HOG 2.8B
- HCM 2.6B
- IPO Year
- HOG N/A
- HCM N/A
- Fundamental
- Price
- HOG $26.83
- HCM $16.01
- Analyst Decision
- HOG Buy
- HCM Sell
- Analyst Count
- HOG 7
- HCM 1
- Target Price
- HOG $30.00
- HCM $13.75
- AVG Volume (30 Days)
- HOG 1.7M
- HCM 56.9K
- Earning Date
- HOG 10-23-2025
- HCM 08-07-2025
- Dividend Yield
- HOG 2.69%
- HCM N/A
- EPS Growth
- HOG N/A
- HCM N/A
- EPS
- HOG 1.93
- HCM 0.53
- Revenue
- HOG $4,474,610,000.00
- HCM $602,197,000.00
- Revenue This Year
- HOG N/A
- HCM N/A
- Revenue Next Year
- HOG $4.11
- HCM $15.49
- P/E Ratio
- HOG $13.92
- HCM $5.91
- Revenue Growth
- HOG N/A
- HCM N/A
- 52 Week Low
- HOG $20.45
- HCM $11.51
- 52 Week High
- HOG $36.94
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- HOG 37.81
- HCM 48.16
- Support Level
- HOG $27.89
- HCM $17.19
- Resistance Level
- HOG $29.22
- HCM $16.35
- Average True Range (ATR)
- HOG 0.95
- HCM 0.29
- MACD
- HOG -0.35
- HCM -0.01
- Stochastic Oscillator
- HOG 7.32
- HCM 21.74
About HOG Harley-Davidson Inc.
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring segments, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 37% of the heavyweight domestic market in 2024.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.